Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01623076 · ClinicalTrials.gov registry record
The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
A clinical trial of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, sponsored by University of Texas Southwestern Medical Center.
- Active
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT01623076 is a study of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder that is active but no longer recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 150 participants, below the 493-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01623076, a study of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder, is active but no longer recruiting, sponsored by University of Texas Southwestern Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and samples from patients prospectively to gain a better understanding of the disease. We are seeking to understand why some patients respond to medications, while others do not. We also seek to understand what happens biologically, preceding relapses. Gathering these data and samples will allow researchers to identify new ways of diagnosing and treating these diseases. Data and samples will be shared with researchers around the world to support collaborative efforts to treat these conditions.
Conditions Studied
Study Locations (1)
Texas
- The University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2012-06 |
| Est. Completion | 2030-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01623076
The ClinicalTrials.gov registry entry for NCT01623076 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 493-participant average among 7 other Neuromyelitis Optica trials with a reported enrollment target (70% lower). The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Neuromyelitis Optica appearing as the primary indexed condition, and to 0 interventions.
NCT01623076 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01623076 about?
NCT01623076 is a clinical study titled "The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders". This study seeks to determine the biologic causes of inflammation in patients with Transverse Myelitis (TM) Neuromyelitis Optica Spectrum Disorder (NMOSD) and related conditions. While patients will be treated according to decisions with their treating physician, this study will collect data and sam...
What is the current status of trial NCT01623076?
This trial is currently active not recruiting. The enrollment target is 150 participants. The study started on 2012-06. Estimated completion is 2030-06.
What conditions does trial NCT01623076 study?
This clinical trial studies the following conditions: Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Optic Neuritis, Transverse Myelitis.
Who is sponsoring clinical trial NCT01623076?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01623076 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neuromyelitis Optica
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder
RECRUITING
-
Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD
RECRUITING · NA
-
Biobank For MS And Other Demyelinating Diseases
ACTIVE NOT RECRUITING
-
A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease)
COMPLETED · Phase 4
-
High Frequency Impulse Therapy for Neuropathic Pain in NMOSD
COMPLETED · Phase 2
-
An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.